Cancer of Head and Neck, Cervical Cancer, Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Small-cell Lung Cancer, Triple Negative Breast Cancer, Urothelial Carcinoma
Conditions
Brief summary
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Detailed description
This study will establish a prospective cohort of pre-treatment tumor specimens with correlated de-identified clinical and demographic data and tissue histology from cancer patients who are undergoing treatment with PD-1/PD-L1 inhibitors. Patients who have undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled. The study will not require a study-specific tumor biopsy; any biopsies taken prior to treatment as part of standard of care are eligible for this study. Biopsies must not have been taken after immunotherapy treatment began. Participants will be asked to provide their consent for the potential use of their biospecimens in subsequent studies for the development and validation of a diagnostic test.
Interventions
DIAGNOSTIC_TESTOncoPrism™ assay
OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
Sponsors
Curebase Inc.
Cofactor Genomics, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject must have a disease of interest. Specifically, subject must have one of: 1. head and neck squamous cell carcinoma (HNSCC) 2. non-small-cell lung cancer (NSCLC) 3. small cell lung cancer (SCLC) 4. urothelial carcinoma (UCC) 5. gastric or gastroesophageal junction adenocarcinoma 6. cervical cancer 7. esophageal squamous cell carcinoma (ESCC) 8. triple-negative breast cancer (TNBC) 9. hepatocellular carcinoma (HCC) 10. renal cell carcinoma (RCC) 11. colorectal cancer (CRC) 2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer. 3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy. 4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy. 5. Willing to provide electronic informed consent per IRB-approved protocol. 6. Able to speak, read, and comprehend English fluently. 7. Subject is 18 years of age or older. 8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.
Exclusion criteria
1. Inability or unwillingness to provide informed consent. 2. Subject who does/did not have one of the cancers listed above (other histologies). 3. Subject has already participated in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PD-L1/PD-1 inhibitor response | 6 months | No response to treatment with PD-L1/PD-1 inhibitor and response to treatment with PD-L1/PD-1 inhibitor. |
Countries
United States
Contacts
Primary ContactClinical Trial Coordinator
Outcome results
None listed